Purpose. Hantavirus infections cause severe haemorrhagic fever with renal syndrome (HFRS) in humans and are associated with high fatality rates. In 2017, numerous outbreaks were reported in China and Germany. This represents a significant public-healthcare issue with no effective HFRS vaccines that offer a long-term immune response. In this study, we investigated the long-term humoral and cellular immune responses and protective immunity of Hantaan virus (HTNV) granulocyte-macrophage colony stimulating factor (GM-CSF) and CD40 ligand (CD40L) virus-like particles (VLPs) in mice.
INTRODUCTION
Haemorrhagic fever with renal syndrome (HFRS) is a lethal zoonotic disease caused by hantavirus. Given that no USA Food and Drug Administration (FDA)-approved vaccine is currently available, the exploration of prophylactic vaccines and detection methods for hantavirus is a priority. Environmental changes have a huge impact on the emergence and re-emergence of certain infectious diseases [1] .
Two climatic variables, temperature and rainfall, play key roles in the ecology of the hantavirus system [2] . In 2017, HFRS outbreaks were reported in China and Germany. By November 20th 2017, more than 878 people were infected in Shaanxi province, China, alone (statistical data from the Centers for Disease Control, Shaanxi province, China). In Germany, 672 people were infected before June 14th 2017 (www.n-tv.de/panorama/Faelle-von-Hantavirus-nehmenrasant-zu-article19895491.html). Hantavirus outbreaks are driven by a confluence of cyclic dynamics of striped field mice (Apodemus agrarius) populations and climate variability at both seasonal and interannual cycles [2] . Thus, Hantaan virus (HTNV) infection outbreaks occur when climatic conditions are favourable for both rodent population growth and virus transmission [2] .
HTNV causes HFRS [3] . The major symptoms of HFRS are sudden fever, headache, low backache and orbital pain; it is characterized by signs of reddening, thrombocytopenia, vascular leakage and acute or permanent kidney failure [4] . Obviously, these outbreaks have raised public concern and, thus, the need for an HTNV prophylactic vaccine is an urgent priority.
China is the most seriously affected country, accounting for over 90 % of total HFRS cases worldwide [5] . Since the first inactivated rodent brain-or cell culture-derived HFRS vaccines were developed in the early 1990s, HFRS cases have significantly dropped to less than 20 000 per year [6] . However, China still has the highest number of HFRS cases and deaths in the world [7] . Despite the case reduction, inactivated vaccines have several drawbacks, such as unsatisfactory levels of long-lasting neutralizing antibody titres, loss of efficient long-term cell immunity protection against HTNV infection, and safety concerns with animal-derived virus material or virulence restoration [8] .
In comparison, virus-like particle (VLP)-based vaccines safely and consistently induce high titre and durable antibody responses in humans. This has been clearly demonstrated against the human papillomavirus (HPV). Several FDA-approved vaccines, including HPV VLP vaccines Cervarix [9] and Gardasil [10] , and HBsAg VLP-based vaccine Sci-B-Vac [11] , provide cross protection for different HPV serotypes, and induce ten times higher neutralizing antibodies than a natural infection status [10] . More recently, VLP vaccines against human immunodeficiency virus [12] and rotavirus [13] have shown great promise in clinical trials. These successes encouraged us to use similar strategies in the development of HTNV vaccines.
The HTNV viral genome contains three fragments, large (L), median (M) and small (S), which encode RNA-dependent RNA polymerase (RdRp), membrane glycoprotein (GP) and nucleoprotein (NP), respectively. NP with strong immunogenicity has several T cell epitopes. VLPs that mimic natural virus can provide a way to combine both GP and NP to boost both humoral and cellular immune responses. The morphology and protein compositions of the VLPs were verified in our previous study [14] . Granulocyte-macrophage colony stimulating factor (GM-CSF) and CD40 ligand (CD40L) are well-known immunopotentiators that enhance the magnitude, type, onset and duration of acquired immune response [15] . Engagement of CD40 with CD40L induces dendritic cell maturation and activation, and facilitates immunoglobulin class switching and affinity maturation, all vital to the adaptive immune response [16] . GM-CSF is a multifunctional cytokine that mediates the proliferation, activation and differentiation of macrophages and dendritic cells [17] . Incorporation of CD40L and GM-CSF on the surface of VLP vaccines augments the efficacy of VLP antigens [15] . HTNV VLPs in dihydrofolatereductasedeficient (dhfrÀ) Chinese hamster ovary (CHO) cells were produced by co-transfection with pCI-S and pCI-M, pCI-S and pCI-M-CD40L, and pCI-S and pCI-M-GM-CSF. Purified HTNV VLP proteins were confirmed using SDS-PAGE, Coomassie blue-stained gels and Western blots. The expected molecular masses of Gn, Gc, NP and CD40L/GM-CSF (70, 55, 48 and 37.5/29 kDa, respectively) were observed in purified HTNV VLPs. All the VLPs had the desired composition both in morphology and protein composition after purification. Our previous studies validated that CD40L/GM-CSF decorated HTNV VLPs (VLP-CD40L; VLP-GM-CSF) presented greater immunogenicity compared with undecorated versions. Our previous data also showed that mice inoculated with VLP-CD40L or VLP-GM-CSF subcutaneously produced higher titres of neutralizing antibodies compared with mice inoculated with undecorated VLPs or traditional inactivated-HTNV vaccine. Titres of NP-specific antibody IgG2a/IgG, an indicator of humoral protective effect after viral infection, were higher in mice immunized with VLP-CD40L or VLP-GM-CSF compared with undecorated VLP or inactivated-HTNV vaccine. Finally, our group found that, compared with undecorated HTNV VLP, vaccination with VLP-GM-CSF and VLP-CD40L increased HTNV-specific cellular immune responses, manifested as a higher yield of IFN-g and IL-2 secreted by spleen cells, and greater cytotoxicity of cytotoxic T lymphocytes (CTLs) [14] . In the present study, we measured the long-term immune protection of incorporated HTNV VLPs (VLP-CD40L and VLP-GM-CSF) to assess viability as a clinical application. We hypothesized that HTNV VLPs possess more effective long-term protective potency compared with traditional HTNV inactivated-virus vaccines. Our results from immunological tests and viral challenge confirm the stable long-term immune potency of HTNV VLPs against HTNV infection and a higher titre of neutralizing antibody for at least 6 months in mice. In addition, HTNV-specific cellular immune responses were recorded with higher expression of IFNg and CTL responses. No significant alteration was observed in the organs of mice after immunization with the VLPs. We also anticipated repeat boosts would supplement the immune efficacy of HTNV VLPs. Indeed, the results showed that boosts with initial immunization promoted humoral and cellular immune responses. These data provide new insights into the development of HTNV vaccines.
METHODS Animals
All applicable institutional and/or national guidelines for the care and use of animals were followed. Adult female C57BL/6 mice (4 weeks old) were purchased from the animal research centre of the Fourth Military Medical University (Xi'an, China). The mice were housed in isolated and ventilated cages. All experiments were performed in accordance with protocols approved by the Fourth Military Medical University Medical Ethics Committee (approval no. XJYYLL-2014508). The animals were acclimated to the laboratory environment for 5-7 days before use. While in their home cage environment, the animals were allowed free access to a standard animal diet and tap water. The animals were deeply anesthetized using inhaled isoflurane (1-3 % or as needed) before all operations. All efforts were made to minimize animal suffering, to reduce the number of animals used and utilize alternatives to in vivo experiments whenever appropriate or feasible.
Cells and viruses
Vero E6 cells (a green monkey kidney epithelial cell line; American Type Culture Collection) were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (HyClone) that was supplemented with 10 % fetal bovine serum (FBS; HyClone). Dhfr-deficient CHO cells (dhfrÀ cells, purchased from the Culture Collection of the Chinese Academy of Science) were maintained at 37 C with 5 % CO 2 in ISCOVE's modified Dulbecco's modified Eagle's medium (DMEM) (Gibco) supplemented with 10 % FBS (Gibco), 2 % HT mix (Sigma) and 100 nM methotrexate (Sigma). Mouse macrophage cells and bone marrow cells were separated from healthy C57BL/6 mice and similarly cultured in DMEM supplemented with 10 % FBS. HTNV strain 76-118 was kept in our lab and was propagated in Vero E6 cells and the viral titres were measured by ELISA [18] . All related experiments were performed in a biosafety level 3 (BSL-3) setting and based on the International Laboratory Biosafety Manual [19] .
HTNV VLPs and commercial inactivated-HTNV vaccine DhfrÀ cells were co-transfected with pCI-S and pCI-M, pCI-S and pCI-M-CD40L, or pCI-S and pCI-M-GMCSF, and were cultured for 24 h after transfection [14, 18] . Cells were washed with Dulbecco's PBS before replacing the culture medium with serum-free CHO medium (HyClone). Supernatants were collected 72 h after transfection. Cultured supernatants containing VLPs were harvested and collected by low-speed centrifugation at 800 g. for 10 min at 4 C, followed by ultracentrifugation at 160 000 for 60 min to pellet the VLPs. VLPs were suspended in PBS at 4 C [14, 18] . Commercial inactivated-HTNV vaccines were purchased from the WeixinBio company.
Antibodies mAb 1A8 (an anti-HTNV neutralizing mAb that can recognize HTNV nucleocapsid protein directly), mAb HRP (horseradish peroxidase)-conjugated 1A8 (specific for the HTNV NP) [20] and HTNV GP6 antigen peptide (specific for HTNV CTL epitope) [21] were prepared in our laboratory. FITC-conjugated goat anti-mouse IgG antibodies were purchased from BD Biosciences. HRP-linked polyclonal antibody to staphylococcal protein A (HRP-SPA) was purchased from Bersee Biomart.
Immunization schedule
Experiments with mice were conducted in compliance with a protocol approved by the Institutional Animal Care and Use Committee based on the Ethical Principles in Animal Experimentation. Specific pathogen-free C57BL/6 mice aged 4 weeks were divided into five groups with ten mice per group randomly, five of the mice were boosted 10 days before challenge. Animals were inoculated subcutaneously with VLP-CD40L, VLP-GM-CSF, undecorated HTNV-VLP, inactivated-HTNV vaccines (100 µg per mouse) or 100 µl 0.9 % saline (w/ v) on days 0, 14 and 28. This 14-day-interval inoculation was initial immunization. Six months later, we collected sera from the mice, and measured the relative index of humoral immunity and cell immunity for long-term memory evaluation. We injected mice with or without a booster dose. Mice were injected intracerebrally with 100 µl infectious HTNV (100 LD 50 ). Three days after infection, mice were euthanized and tissues from heart, liver, spleen, lung and kidney were collected ( Fig. 1 ).
ELISA Measurement of specific antibodies
The serum samples were screened for HTNV-specific antibody by sandwich ELISA using truncated NPs as antigens [14, 20, 22, 23] , purified in our laboratory. HTNV NP (0.15 µg ml
À1
) was coated to each well of 96-well plates and incubated at 4 C overnight. After washing three times with PBS Tween (PBST) and the final concentration of Tween is 0.05 % (v/v), PBST containing 10 % FBS was added to block unsaturated binding sites for 1 h at 37 C. After washing three times with PBST, 100 µl sera from immunized mice, serially diluted with PBS from 1 : 40 to 1 : 1280, were added into the NP-coated 96-well plates. After incubation at 37 C for 2 h, plates were washed with PBST three times, then 100 µl HRP-SPA was added to each well. Plates were incubated at 37 C for 1 h, washed with PBST three times and TMB [diethyl 2,5-di(thiophen-2-yl) terephthalate] solution was added to each well, then the plates were placed in the dark for 20 min at room temperature. A total of 50 µl 2M H 2 SO 4 was added to stop the reaction and the absorbance was measured at a wavelength of 450 nm using a Synergy HT ELISA plate reader. Normal sera from healthy mice were used as a negative control, the P/N value >2.1 was considered 'significant'. We repeated the experiment four times and calculated the geometric mean titre (GMT) of the critical dilution, which was utilized to compare specific antibody titres among all groups.
Measurement of neutralizing antibodies
Vero E6 cells grown in a 96-well tissue culture plate in RPMI-1640 medium supplemented with 10 % FBS were plated at a density of 1Â10 4 cells per 100 µl medium and cultured overnight before testing. The sera from the immunized mice were filtered through 0.22 µm filters, then diluted serially twofold from an initial 1 : 40 dilution to 1 : 1280 with RPMI-1640 medium and mixed with an equal volume of 100 TCID 50 (50 % tissue culture infective dose) HTNV (76-118 strain) (m.o.i.=1). The mixture (100 µl) was transferred to monolayers of Vero E6 cells; a positive control was added with virus only, the negative control was serum from healthy mice mixed with 100 TCID 50 HTNV. After incubating at 37 C for 90 min in a 5 % CO 2 incubator, medium was discarded and samples incubated using DMEM with 10 % FBS at 37 C for 10 days in a 5 % CO 2 incubator. HTNV does not elicit the cytopathic effect so we could not distinguish virus load visibly; therefore, we lysed cells by three consecutive freeze-thaw cycles and centrifuged at 800 g for 10 min at 4 C and collected the supernatant. HNTV load in the cell lysates was detected using indirect ELISA. The mAb 1A8 was used as a coating antibody, and HRP-conjugated 1A8 was used as the detecting antibody. mAb 1A8 was coated to each well of 96-well ELISA plates and incubated at 4 C overnight. Then, the plates were washed with PBST and supernatant (100 µ) was added to each well. After incubation at 37 C for 1 h, plates were washed with PBST and then diluted HRP-1A8 was added to each well. After incubation at 37 C for 1 h, 50 µl TMB was added into each well and the plates placed in dark for 15 min. A total of 50 µl 2M H 2 SO 4 was added to stop the reaction and absorbance was measured at a wavelength of 450 nm, using a standard ELISA plate reader (Bio-Rad). The neutralizing antibody titre was defined according to Karber's method: LgPD50=L+DÂ(S-0.5); L=Lg(critical dilution); D=interval of serial dilution; S=all negative wells/ all wells. The critical dilution was the highest dilution after which there existed 'significant' wells (P/N>2.1) [22] .
Measurement of HTNV NP antigen
Tissues from infected mice were weighed and triturated in PBS. After three consecutive freeze-thaw cycles and centrifugation at 50 000 g for 10 min at 4 C, we collected the supernatant; the total protein was measured by sandwich ELISA. The mAb 1A8 was coated to each well of 96-well plates and incubated at 4 C overnight. The supernatant (100 µl) was added into NP-coated 96-well plates. After incubation at 37 C for 1 h, plates were washed with PBST and then diluted HRP-1A8 was added to each well. Subsequently plates were incubated at 37 C for 1 h, washed with PBST, then TMB solution was added and the absorbance at 450 nm was recorded.
IFN-g and IL-4 enzyme-linked immunospot (ELISpot) assay
The cytokines IFN-g and IL-4 from immunized mice were measured using ELISpot kits (BD Biosciences), according to the manufacturer's instructions. Briefly, ELISpot 96-well plates (supplied with the kits) were coated with 100 µl antimouse IFN-g or anti-mouse IL-4 (5 µg ml À1 in coating buffer) antibodies. The plates were washed twice and blocked with blocking solution for 2 h. A volume of 100 µl freshly isolated splenocytes (1Â10 6 cells) from the immunized mice were subsequently transferred to each well and stimulated with NP or Gn/Gc peptide pools at 37 C for 24 h. The cells were washed and a secondary biotinylated anti-cytokine mAb was added to each well, followed by a streptavidin-HRP and AEC substrate solution system. Finally, the spots were counted using an EliSpot Reader (AID).
Cytotoxicity assay
A previous study verified that macrophages separated from the mouse abdominal cavity can be infected by HTNV 76-118 strain [14] . Macrophages separated from abdominal cavities of healthy mice were infected with 100 TCID 50 (m. o.i.=1) HTNV 76-118 strain at 37 C for 3 days, excessive virus was then washed away and DMEM supplemented with 10 % FBS was added to the cells. The macrophages were tested by immunofluorescence to assess the infection rate 2 days later; the HTNV infected macrophages were used as target cells. Splenocytes were separated from immunized mice (effector cells), prepared as described above, and 20 µg HTNV GP6 ml À1 was added to stimulate spleen cells, the effector cells were cultured at 37 C for 24 h in a 5 % CO 2 incubator. U-shaped 96-well plates were used and a volume of 100 µl target cells (1Â10 4 cells) was added to each well. Then, a series of different numbers of splenocytes were applied to the wells (1Â10 6 cells, 5Â10 5 cells, 2.5Â10 5 cells, Fig. 4 . Cytokine secretion increased after VLP immunization in mice after 6 months. (a) IFN-g levels in sera after immunization with HTNV VLPs or inactivated-HTNV vaccine before and after boost. IFN-g levels were significantly higher in VLP groups compared with inactivated-HTNV vaccine (P<0.001). There was no significant difference among undecorated HTNV VLP, VLP-CD40L and VLP-GM-CSF (P>0.05) before boost. IFN-g levels were significantly higher after boost, with the greatest change in the VLP-GM-CSF group. (b) IL-4 levels showed no significant change in the sera of mice immunized with HTNV VLPs or inactivated-HTNV vaccine before and after boost. One-way ANOVA was used for statistical evaluation: **, P<0.001; *, P<0.05. n=5.
1.25Â10 5 cells)
. The plates were incubated at 37 C for 6 h, and lactate dehydrogenase release was assessed. The percentage of specific lysis was calculated. A CytoTox 96 nonradioactive cytotoxicity assay kit (Promega) was used, according to the manufacturer's instructions.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted using Axygen kits following the manufacturer's instructions and reverse transcribed into cDNA using a reverse transcription kit (TaKaRa). Copies of HTNV S segments were counted through a qRT-PCR assay using a SYBR green RT-PCR kit (TaKaRa), the primers were designed based on the sequence alignment of the S segment of the HTNV standard strain 76-118, the following sequences produced by TaKaRa Biotechnology were used: forward primer, 5¢-TACAGAGGGAAATCAATGCC-3¢ (nucleotides at the S segment of HTNV strain 76-118 : 56-75); reverse primer, 5¢-TGTTCAACTCATCTGGATCCTT-3¢ (nucleotides 136-157) [24] . qRT-PCR was performed for each cDNA sample in triplicate. qRT-PCR reactions were performed in a 15 µl final reaction volume containing 10 µl SYBR Taq Mix, 1.5 µl each primer, 2 µl RNA template. Thermal cycling was performed in a LightCycler 96 instrument (Roche) as follows: 95 C for 5 min; amplification for 50 cycles of 15 s at 95 C and 30 s at 72 C. The mRNA expression level of each target gene was normalized to the respective GAPDH and analysed.
Haematoxylin-eosin staining Organ tissues were excised and fixed by formalin, then embedded, cut and processed with haematoxylin-eosin stains for pathological assessment.
Statistical analysis
Data were analysed using GraphPad Prism 6 software. Statistical analysis of antibody titres, viral antigen and mRNA were performed using one-way ANOVA, titre was expressed as the GMT. Results of the cytokine ELISpot assay were compared by one-way ANOVA, and CTL assay was compared using one-way ANOVA and performed as percentage of specific lysis. Comparison between each group was carried out by Student-Newman-Keuls (S-N-K) test. A P value of <0.05 was considered statistically significant.
RESULTS
VLP-CD40L and VLP-GM-CSF increased the anti-NP antibody titre in mice after 6 months Antibody avidity, a measure of overall strength, is a key humoral immunity measure. We measured HTNV NP specific antibodies by sandwich ELISA, and HTNV neutralizing antibodies by indirect ELISA. We inoculated mice with undecorated VLP, VLP-GM-CSF, VLP-CD40L, inactivated-HTNV vaccine or 0.9 % saline (w/v) alone. Antibody titres obtained from ELISA were calculated as GMTs. After 6 months, we evaluated specific anti-HTNV NP antibodies in the mice immunized with VLPs. We found the NP-specific antibody titre in mice immunized with undecorated HTNV VLPs was 23.78. The specific anti-NP antibody titre of mice immunized with HTNV VLPs incorporated with GM-CSF or CD40L were 40.00 and 47.57, respectively. This was significantly higher compared with inactivated-HTNV vaccine (2.115) (P<0.05). Furthermore, results showed that VLP-CD40L produced the most specific anti-NP antibodies (Fig. 2a) . Of note, levels of specific antibodies in inactivated-HTNV vaccine immunized mice dropped to the baseline Fig. 5 . CTL efficiency was enhanced by VLPs in mice 6 months after immunization before and after boost. HTNV NP-specific cytotoxicity of immunization-activated spleen cells against C57BL/6 mouse macrophages was induced by different VLPs and vaccines. The spleen cells from different immunized mice were harvested and the percentage of specific lysis of CTLs on macrophages was determined by cytotoxicity assays. (a) The long-term HTNV NP-specific cytotoxicity 6 months after immunization was similar between saline and vaccine groups, which is indicative of the loss of long-term cytotoxicity efficacy of the inactivated-HTNV vaccine. (b) Inactivated-HTNV vaccine and VLPs showed an enhanced killing effect after boost, VLP-GM-CSF showed the highest cytotoxic effect against target cells (P<0.05). Two-way ANOVA was used for statistical evaluation: **, P<0.001; *, P<0.05. n=5.
after 6 months, with no significant difference compared with the saline group.
We boosted immunization by inoculating mice again with the same dosage scheme 10 days later. Each group showed significant antibody re-bounce. The results showed significantly more antibodies in those immunized with VLP-GM-CSF or VLP-CD40L compared with undecorated HTNV VLP (P<0.05). In addition, mice immunized with VLP-CD40L produced more HTNV NP-specific antibodies compared with the VLP-GM-CSF group (P<0.05) (Fig. 2b) . These results demonstrate immunization with VLP-GM-CSF or VLP-CD40L effectively generates anti-NP specific antibodies for an extended period of 6 months, which is significantly longer than traditional inactivated-HTNV vaccines.
VLP-CD40L and VLP-GM-CSF increased the HTNV neutralizing antibody titre in mice after 6 months A neutralizing antibody titre test was performed on monolayers of Vero E6 cells grown in a 96-well tissue culture plate with the HTNV 76-118 strain. Our results showed the mean titre of neutralizing antibodies in mice immunized with inactivated-HTNV vaccine (33.64) was significantly lower compared with VLP-GM-CSF (47.57) and VLP-CD40L (80.00) groups (P<0.05). VLP-CD40L-immunized mice secreted the most neutralizing antibody (Fig. 3a , Table 1 ). After boosting, the HTNV neutralizing antibody titre of each group increased, with VLP-CD40L showing highest efficacy in inducing neutralizing antibody secretion (Fig. 3b, Table 1 ). However, only VLP-CD40L showed higher neutralizing antibody titre after boost compared with before boost (P<0.001). These results showed HTNV VLP incorporated with CD40L or GM-CSF optimized humoral immunization efficacy; and more importantly, HTNV VLPs conferred superior immune efficacy compared with inactivated-HTNV vaccines after boost.
Cytokine secretion increased after VLP immunization in mice after 6 months Given that HTNV VLPs promote HTNV-specific IFN-g secretion [14] , we assessed cellular immunity in mice by detecting the expression levels of IFN-g and IL-4 by ELISpot assay. We also measured CTLs with a traditional CTL assay. ELISpot assay results showed that HTNV-specific IFN-g significantly increased after HTNV VLP vaccination (P<0.05). We found no significant difference among VLP, VLP-CD40L and VLP-GM-CSF (P>0.05). After boosting, the number of IFN-g spots from the VLP-GM-CSF group was highest compared with the other groups (P<0.05) Fig. 6 . VLP immunization blunted viral antigen against a lethal HTNV challenge in C57BL/6 mice. Sandwich ELISA results of HTNVspecific antigens in various tissues of immunized mice 6 months after being challenged with HTNV before and after boost. We used mAb 1A8 to detect HTNV nucleocapsid protein (NP) levels. NP levels were significantly lower in the liver, spleen, lung and kidney tissues of VLP groups compared with controls. One-way ANOVA was used for statistical evaluation: **, P<0.001; *, P<0.05. n=5. (Fig. 4a) . However, IL-4 levels showed no significant change in any group before or after boost (P>0.05) (Fig. 4b) .
CTL efficiency was enhanced by VLPs in mice 6 months after immunization before and after boost To further determine vaccine effectiveness, we also measured CTLs with a traditional CTL assay. The cytotoxicity capacity of spleen cells against HTNV-infected C57BL/6 mouse macrophages is considered vaccination-elicited cytotoxicity activity potency, which positively correlates with effector to target (E:T) ratio. We found the cytotoxicity efficiency was highest when the E:T ratio was 100 : 1 (Fig. 5a) . The inactivated-HTNV vaccine group showed a similar cytotoxic effect as the saline group 6 months after inoculation (P>0.05). The cytotoxic activities of different VLPs were significantly higher compared with the inactivated-HTNV vaccine group (P<0.05), with no difference among the three HTNV VLPs (P>0.05) (Fig. 5a) . Additionally, we verified the memory cytotoxicity of each group by comparing results before and after boost. The results showed HTNV VLPs had a greater killing effect compared with inactivated-HTNV vaccine (P<0.05) and VLP-GM-CSF was the most cytotoxic against target cells after boost (P<0.05) (Fig. 5b) . Therefore, we argue HTNV VLPs induce continual HTNV-specific cytotoxic activity and memory cytotoxicity, while inactivated-HTNV vaccines offer no additional effect on promoting long-term cell immunization response.
VLP immunization blunted viral antigen against a lethal HTNV challenge in C57BL/6 mice Successful vaccination regimes are characterized by low viral loads after lethal pathogen challenge. Our previous work verified viral loads in mouse tissue reach the highest levels 3 days after infection [14] . Therefore, in this study we used the same time point to assess virus antigen levels in various mouse tissues after challenging with the live HTNV strain 76-118 by sandwich ELISA. Results showed levels from inactivated-HTNV vaccine immunized mice were similar to the saline group (P>0.05) (Fig. 6 ). In addition, HTNV-specific antigen levels for all groups were low and unchanged in heart and brain tissues before and after boost (Fig. 6a, f) . Most importantly, we found HTNV antigen levels in liver, spleen, lung and kidney from VLP groups were significantly reduced compared with the saline group (P<0.05) (Fig. 6b, c, d, e) . This demonstrates that HTNV VLPs reduce virus load more effectively than inactivated-HTNV vaccine. Fig. 7 . Nucleic acid loads were reduced in mice after VLP immunization. qRT-PCR quantitation of the nucleic acid levels in the tissues of immunized mice 6 months after immunization, challenged with HTNV, before and after boost. Total RNA was extracted and reverse transcribed to cDNA. A specific primer was used to detect the S segment of the HTNV standard strain at sequence position 76-118A; GAPDH was used as a control. A Student's t-test was used for statistical evaluation: **, P<0.001; *, P<0.05. n=5.
Nucleic acid loads of HTNV were reduced in mice after VLP immunization Previous work showed that HTNV nucleic acid load is proportional to disease severity [24] . Therefore, we evaluated HTNV-specific nucleic acid loads using qRT-PCR of the tissues of immunized C57BL/6 mice after being challenged with HTNV ( Fig. 7a-f) . The results showed no significant difference in the HTNV-specific nucleic acid levels in liver, lung and kidney tissues of the saline group and inactivated-HTNV vaccine groups (P>0.05). This is indicative that inactivated vaccines provide immunity for less than 6 months. Most importantly, our results showed the HTNV-specific mRNA levels in the liver, lung and kidney tissues from VLP groups were significantly lower compared with control groups (P<0.05). Additionally, HTNV-specific nucleic acids decreased in VLP and activated vaccine groups (Fig. 7b, d , e). These results are indicative that vaccination programs using HTNV VLP vaccines can eradicate HTNV infection in mice effectively.
Pathological changes in tissue from immunized mice challenged with HTNV before and after boost To determine whether molecular changes also resulted in physiological significance, we analysed the pathology of the mice as well. The results showed that the saline group suffered from inflammatory swelling around the peripheral vessels in the liver, mild inflammatory cell infiltration in the hepatic interstitium (Figs S1 and S2, available with the online version of this article), slight haemorrhage in the alveolar space, broadened alveolar wall interstitium, lymphocyte infiltration around pulmonary vascular and interstitium tissue, capillary congestion and broadened alveolar septa (Fig. 8a) , and scattered inflammatory cell infiltration in the kidney (Figs S3 and S4 ). In addition, mild dilation of the spleen was visible in gross specimens, but specimens were without abnormalities under microscopic viewing. No apparent pathological changes were found in the heart and brain tissues (data not shown). Furthermore, we found similar pathological changes in the inactivated-HTNV vaccine group, pointing out that the inactivated-HTNV vaccine had no protective effect in mouse infected with HTNV (Fig. 8b) . Data clearly showed that all VLP groups experienced significantly less pathological damage compared with both control groups (Fig. 8c, d, e ). There were no significant pathological changes in the inactivated-HTNV vaccine group or HTNV VLP groups after vaccine boost (Fig. 9) . Taken together, these results showed that the immunization of C57BL/6 mice with HTNV VLPs increased virus clearance and reduced pathological changes.
DISCUSSION
VLPs have been used over the past 30 years as versatile vaccine development tools given their distinctive immunological characteristics [25] . VLPs lack viral nucleic acids to prevent replication, this makes them intrinsically safer than attenuated virus vaccines [26] . Most importantly, VLPs are innately immunogenic, as they resemble infectious virus structurally and antigenically. This induces high-titre and long-lasting antibody responses at low doses [27] . Recently, two VLP-based vaccines were approved for human use against hepatitis B virus and HPV [28] . Mice immunized intranasally with influenza H5N1 VLPs developed high levels of H5N1-specific antibodies and were 100 % protected against a high dose of homologous H5N1 virus infection at 30 weeks after immunization [29] . In addition, HPV type 6/ 11/16/18 L1 VLP vaccine induced high-efficacy and stable anti-HPV antibodies for at least 5 years in humans [30] . Landry et al. verified that inoculability of HA VLP vaccines elicited both strong antibody response and cross-reactive memory T cells that persisted for at least 6 months after vaccination [31] . In addition, respiratory syncytial virus (RSV) VLP vaccines were effective in stimulating proliferation of long-lived RSV-specific, T-cell-dependent neutralizing antibody-secreting cells and RSV-specific memory responses [32] . In comparison, inactivated-HTNV vaccines were limited by loss of long-term efficacy [8] . Indeed, previously we found it difficult to detect specific anti-HTNV NP antibodies, neutralizing antibodies, a long-lasting IFN-g response or CTL cytotoxicity 6 months after initial immunization with inactivated-HTNV vaccines [22] . Possible explanations may be loss of virulence or biological activity, which leads to quicker clearance by the immune system. The inactivated-HTNV vaccines used as controls in this test were mainly applied in Asia; this appliance contributed to a steady drop of HFRS, but its worldwide acceptance was limited by response instability or the loss of long-term efficacy [4, 5] . Scientists reported a long-term immunogenicity and safety of inactivated-HTNV vaccine (Hantavax) in healthy adults, the seropositive rate of the Hantavax-induced antibody was maintained above 40 % 1 year after the booster dose but decreased markedly after that, and they didn't mention cellular response evaluations [33] . Jiang et al. reported that a recombinant DNA vaccine of HTNV Gn and LAMP1 (pVAX-LAMP/Gn) can induce long-term immune protection in mice on day 180, but they did not test cell immune response. We used a similar immunization schedule, but we gave the final booster on day 218. Immunization with pVAX-LAMP/Gn performed steady and stable positive seroconversion and the strongest neutral antibody recall compared with the inactivated vaccine, but the inactivated vaccine can induce a higher specific antibody titre than pVAX-LAMP/Gn [7] . As far as we know, our study is the first to report on the long-term VLP-initiated immune responses against HTNV, both humoral and cellular, and the HTNV VLPs did induce a better humoral and cellular immune response than inactivated vaccine.
Previously, we successfully constructed undecorated HTNV VLP, VLP-CD40L and VLP-GM-CSF, and verified immune efficacy in mice 7 days after immunization. Results showed that HTNV VLPs (VLP-CD40L; VLP-GM-CSF) elicited stronger immune protective responses [14] . This current study aimed to explore the long-term immunization efficacy of incorporated HTNV VLPs, and demonstrated enhanced duration and functional activation of cellular and humoral immune responses compared with traditional inactivated-HTNV vaccine or undecorated HTNV VLP. Most subunit vaccines and recombinant protein vaccines lack the inherent pro-inflammatory properties of attenuated organisms, and decay more rapidly than those generated from live organisms, thereby requiring booster immunizations [34] . Thus, we also measured immune responses before and after boosts.
Given that innate immunity is an important requirement for the induction of effective immune responses following vaccination, we measured B-cell and T-cell responses to HTNV VLPs. Specific anti-NP antibodies and neutralizing antibodies were used to evaluate B-cell function. The magnitude of the T-cell response generated by a vaccine can be assessed by measuring the capacity to secrete soluble factors, such as IFN-g and IL-4 [35] . Our results confirmed that incorporation of VLP-GM-CSF or VLP-CD40L into HTNV VLP resulted in higher antibody levels, a long-lasting and specific T-cell response, and CTL cytotoxicity after 6 months. A steady and stable antibody titre and strong antibody recall were maintained after the boost. We found that IFN-g, an important cytokine secreted by Th1 type T cells, was significantly increased in immunized mouse sera. However, the results showed that IL-4, which is secreted by Th2 type T cells, did not change after immunization. We inferred that HTNV VLPs promoted cell immunity by activating Th1 cells.
Additionally, our data showed that the vaccine protection potency 6 months after initial immunization with the chimeric HTNV VLPs was robust. Virus antigen loads in mice immunized with VLP-CD40L or GM-CSF were low, implying that vaccinated animals showed increased resistance to HTNV. Vaccinated mice showed greater immunogenic results compared with inactivated-HTNV vaccine group. Effective humoral and cellular immune responses, and strong resistance to HTNV infection, are key characteristics for a reliable HTNV VLP vaccine. Thus, moving the HTNV VLP vaccine from bench to bedside should be expected.
However, application of HTNV VLPs does come with future challenges. We know that titres of anti-NP specific antibodies in sera from mice immunized with VLP-CD40L or VLP-GM-CSF after 7 days were significantly higher compared with those at 6 months [14] . Also, transient transfection in CHO cells was far less productive; we need to work on constructing cell lines that express VLP stably. Furthermore, the long-term safety of HTNV VLPs needs to be clarified and optimized in future research.
Conclusion
In conclusion, our work verified that incorporation of HTNV VLP with CD40L or GM-CSF is a feasible approach to reduce HFRS incidence and warrants further development. Our future studies will be focused on increasing the stability and immunogenicity through purification and biochemical modification of HTNV VLPs. Our basic research and preclinical data on efficacy may be applied to clinical trials of vaccines in humans.
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